MASH

News

EMA panel endorses AI for MASH clinical trials

PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.

News

Slide showing non-alcoholic fatty liver disease (NAFLD)

Novo Nordisk will file semaglutide for MASH next year

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US

R&D

The growing challenge of conducting clinical trials for meta...

Liver disease is on the rise around the world, posing a significant health concern.

Patients

Exploring the role of pharmacy and self-care in the fight ag...

Globally, the incidence of fatty liver disease is increasing at a concerning rate, yet, the solution could be simple.

News

Boehringer, Lilly face off in MASH at EASL

Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associa

News

Madrigal Pharma is first over the MASH finish line

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that ha

EMA panel endorses AI for MASH clinical trials

Novo Nordisk will file semaglutide for MASH next year

The growing challenge of conducting clinical trials for meta...

Exploring the role of pharmacy and self-care in the fight ag...

Boehringer, Lilly face off in MASH at EASL

Madrigal Pharma is first over the MASH finish line

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

MASH

Editor's Picks